Project Grant R01CA285425
Award Date 5/8/26
Completion Date 4/30/31
Dollars Obligated $628K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10029, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $697,131 Project Grant under the Cancer Biology Research program (CFDA 93.396) on May 1, 2026, with a completion date of April 30, 2031. This five-year research initiative will investigate the myeloid-stromal axis in colorectal cancer (CRC), specifically examining how interactions between macrophages and cancer-associated fibroblasts (CAFs) suppress anti-tumor immunity and promote tumor...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $147,083 Project Grant to Icahn School of Medicine at Mount Sinai under the Cancer Research Manpower program (CFDA 93.398) for the period August 1, 2025 through July 31, 2027. This award supports mentored postdoctoral research training through an NCI Pathway to Independence Award (K99/R00) mechanism, funding a career development project titled "Deconstructing Pathogenic Myelopoiesis in Cancer Immunosuppression and...
- Federal Grant Award Summary The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai a $682,886 Project Grant under the Cancer Biology Research program (CFDA 93.396) effective May 1, 2026, through April 30, 2031. This five-year research initiative focuses on elucidating the role of ATAD2 (AAA-Adenosine Triphosphatase Domain-containing protein 2) in prostate cancer progression and metastasis. The project addresses a critical clinical need by investigating the mechanisms...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $2.68 million Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai, with an award date of August 1, 2025, and a completion date of July 31, 2030. This five-year research initiative, led by Principal Investigator James Manfredi, investigates mutant p53 protein's role in tumorigenesis, invasion, and metastasis. The program comprises four integrated...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a $2.69 million Project Grant on September 24, 2025, under the Cancer Biology Research program (CFDA 93.396) to investigate the mechanisms and impact of neuregulin 3 (NRG3) induction in bone metastasis. The four-year research initiative, extending through August 31, 2029, will employ molecular and genetic approaches to characterize the NRG3 regulome in the bone microenvironment,...
- Federal Project Grant Award Summary The National Cancer Institute awarded $642,242 through its Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai on May 15, 2026, to support a five-year research project examining the mechanisms of brain metastasis in breast cancer. The project, titled "Function and Therapeutic Implications of NRG3 in Breast Cancer Brain Metastasis," investigates how neuregulin 3 (NRG3), a neuron-associated ligand, promotes the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $169,000 Project Grant under the Cancer Biology Research program (CFDA 93.396) to Icahn School of Medicine at Mount Sinai, effective August 1, 2025, through July 31, 2027. This research grant supports a two-year investigation into epigenetic regulation of melanoma-associated fibroblast plasticity, specifically examining how histone variant dysfunction affects the tumor microenvironment (TME). The principal...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant of $682,886 under the Cancer Biology Research program (CFDA 93.396) to investigate the role of ATAD2 (AAA+ ATPase Containing Domain Protein 2) in prostate cancer progression and metastasis. The five-year project, which commenced May 1, 2026 and concludes April 30, 2031, addresses the critical clinical challenge of metastatic prostate cancer, which remains the...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under its Cancer Treatment Research program (CFDA 93.395), awarded Cold Spring Harbor Laboratory a $778,873 Project Grant on June 23, 2025, with a completion date of May 31, 2030. This award funds research to identify and validate SOAT1 (Sterol-O-Acyl Transferase 1) as a therapeutic target in pancreatic ductal adenocarcinoma (PDAC). The research will utilize genetically engineered mouse models and inducible degron systems...